Festi hf. (ICE:FESTI)
Iceland · Delayed Price · Currency is ISK 302.00
-2.00 (-0.66%)
Aug 5, 2025, 3:29 PM GMT
Verve Therapeutics Income Statement
Financials in millions ISK. Fiscal year is January - December.
Millions ISK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
| 167,567 | 154,463 | 136,251 | 121,398 | 98,736 | 86,260 | Upgrade | |
Revenue Growth (YoY) | 18.99% | 13.37% | 12.23% | 22.95% | 14.46% | 1.49% | Upgrade |
Cost of Revenue | 127,364 | 118,813 | 106,611 | 95,369 | 74,999 | 66,248 | Upgrade |
Gross Profit | 40,203 | 35,650 | 29,640 | 26,029 | 23,737 | 20,012 | Upgrade |
Selling, General & Admin | 20,918 | 18,385 | 15,440 | 13,456 | 11,659 | 10,521 | Upgrade |
Other Operating Expenses | 5,275 | 4,854 | 3,221 | 2,624 | 2,511 | 2,416 | Upgrade |
Operating Expenses | 32,109 | 28,329 | 22,763 | 19,608 | 17,363 | 15,805 | Upgrade |
Operating Income | 8,094 | 7,321 | 6,878 | 6,421 | 6,375 | 4,207 | Upgrade |
Interest Expense | -3,841 | -3,768 | -3,544 | -2,408 | -1,957 | -2,044 | Upgrade |
Interest & Investment Income | 467.75 | 417.65 | 242.26 | 177.8 | 85.92 | 102.11 | Upgrade |
Earnings From Equity Investments | 660.94 | 608.19 | 418.13 | 453.49 | 300.7 | 267.66 | Upgrade |
Currency Exchange Gain (Loss) | 37.18 | 65.74 | -34.3 | 4.61 | 66.95 | 23.28 | Upgrade |
EBT Excluding Unusual Items | 5,420 | 4,644 | 3,959 | 4,649 | 4,871 | 2,556 | Upgrade |
Merger & Restructuring Charges | - | - | - | - | -19.34 | -18.47 | Upgrade |
Gain (Loss) on Sale of Investments | 65.34 | 65.34 | 1.76 | - | 3.93 | - | Upgrade |
Gain (Loss) on Sale of Assets | 113.76 | 99.84 | 36.1 | 70.1 | 569.11 | - | Upgrade |
Asset Writedown | 177.76 | 302.29 | 138.89 | 216.04 | 736.01 | 240.03 | Upgrade |
Pretax Income | 5,777 | 5,112 | 4,136 | 4,936 | 6,161 | 2,778 | Upgrade |
Income Tax Expense | 1,214 | 1,093 | 697.85 | 853.87 | 1,189 | 511.45 | Upgrade |
Net Income | 4,562 | 4,018 | 3,438 | 4,082 | 4,972 | 2,266 | Upgrade |
Net Income to Common | 4,562 | 4,018 | 3,438 | 4,082 | 4,972 | 2,266 | Upgrade |
Net Income Growth | 15.62% | 16.87% | -15.77% | -17.91% | 119.39% | -18.93% | Upgrade |
Shares Outstanding (Basic) | 311 | 306 | 304 | 309 | 321 | 326 | Upgrade |
Shares Outstanding (Diluted) | 315 | 308 | 304 | 309 | 321 | 326 | Upgrade |
Shares Change (YoY) | 3.91% | 1.27% | -1.72% | -3.71% | -1.42% | -1.07% | Upgrade |
EPS (Basic) | 14.66 | 13.13 | 11.31 | 13.19 | 15.48 | 6.95 | Upgrade |
EPS (Diluted) | 14.49 | 13.05 | 11.31 | 13.19 | 15.48 | 6.95 | Upgrade |
EPS Growth | 11.27% | 15.40% | -14.29% | -14.74% | 122.56% | -18.06% | Upgrade |
Free Cash Flow | 8,065 | 5,310 | 5,951 | 27.17 | 6,448 | 1,556 | Upgrade |
Free Cash Flow Per Share | 25.62 | 17.25 | 19.57 | 0.09 | 20.07 | 4.78 | Upgrade |
Dividend Per Share | 4.500 | 4.500 | 3.000 | 3.000 | 5.000 | 3.000 | Upgrade |
Dividend Growth | 50.00% | 50.00% | - | -40.00% | 66.67% | 50.00% | Upgrade |
Gross Margin | 23.99% | 23.08% | 21.75% | 21.44% | 24.04% | 23.20% | Upgrade |
Operating Margin | 4.83% | 4.74% | 5.05% | 5.29% | 6.46% | 4.88% | Upgrade |
Profit Margin | 2.72% | 2.60% | 2.52% | 3.36% | 5.04% | 2.63% | Upgrade |
Free Cash Flow Margin | 4.81% | 3.44% | 4.37% | 0.02% | 6.53% | 1.80% | Upgrade |
EBITDA | 11,788 | 10,435 | 9,464 | 8,559 | 8,539 | 6,227 | Upgrade |
EBITDA Margin | 7.03% | 6.76% | 6.95% | 7.05% | 8.65% | 7.22% | Upgrade |
D&A For EBITDA | 3,693 | 3,115 | 2,586 | 2,138 | 2,165 | 2,020 | Upgrade |
EBIT | 8,094 | 7,321 | 6,878 | 6,421 | 6,375 | 4,207 | Upgrade |
EBIT Margin | 4.83% | 4.74% | 5.05% | 5.29% | 6.46% | 4.88% | Upgrade |
Effective Tax Rate | 21.02% | 21.39% | 16.87% | 17.30% | 19.30% | 18.41% | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.